Important Surgical and Clinical End Points in Neoadjuvant Immunotherapy Trials in Resectable NSCLC

by Jay M. Lee, MD, Anthony W. Kim, MD, Tomasz Marjanski, MD, PhD, Pierre-Emmanuel Falcoz, MD, PhD, Masahiro Tsuboi, MD, PhD, Yi-Long Wu, MD, Shawn W. Sun, PharmD, Barbara J. Gitlitz, MD
Published 2021-10-01

Real-World Scenario of Patients With Lung Cancer Amid the Coronavirus Disease 2019 Pandemic in the People’s Republic of China

by Rui Fu, MD, Lin Wu, PhD, Chao Zhang, MD, Qian Chu, PhD, Jie Hu, PhD, Gen Lin, PhD, Lin Yang, PhD, Ji-Sheng Li, PhD, Xue-Ning Yang, PhD, Jin-Ji Yang, PhD, Qing Zhou, PhD, Yi-Long Wu, MD, Wen-Zhao Zhong, PhD
Published 2020-09-01

Ceritinib Efficacy and Safety in Treatment-Naive Asian Patients With Advanced ALK-Rearranged NSCLC: An ASCEND-4 Subgroup Analysis

by Daniel S.W. Tan, BSc, M.B.B.S., MRCP, PhD, Sarayut Geater, MD, Chong-Jen Yu, MD, PhD, Chun-Ming Tsai, MD, Te-Chun Hsia, MD, Jun Chen, MD, PhD, Meng-Chih Lin, MD, You Lu, MD, Virote Sriuranpong, MD, Cheng-Ta Yang, MD, Paramita Sen, PhD, Fabrice Branle, MD, Michael Shi, MD, Yi-Long Wu, MD
Published 2021-03-01

Outcomes With Pembrolizumab Monotherapy in Patients With Programmed Death-Ligand 1–Positive NSCLC With Brain Metastases: Pooled Analysis of KEYNOTE-001, 010, 024, and 042

by Aaron S. Mansfield, MD, Roy S. Herbst, MD, PhD, Gilberto de Castro, Jr., MD, PhD, Rina Hui, MB, BS, PhD, Nir Peled, MD, PhD, Dong-Wan Kim, MD, Silvia Novello, MD, PhD, Miyako Satouchi, MD, Yi-Long Wu, MD, Edward B. Garon, MD, Martin Reck, MD, PhD, Andrew G. Robinson, MD, Ayman Samkari, MD, Bilal Piperdi, MD, Victoria Ebiana, MD, Jianxin Lin, MS, Tony S.K. Mok, MD
Published 2021-08-01